Fig. 3
From: Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
Ibrutinib inhibits T cell degranulation, cytokine release and proliferation of CLL patient T cells in vitro. CD8 + T cell degranulation (A) and intracellular IFNγ production (B) in PBMC from Healthy Donor (HD, n = 6) or treatment naïve CLL patients (n = 11) incubated with BTKi, or DMSO vehicle control for 18 h prior to activation with T cell stimulation beads for 4 h. C IL-2, IFNγ, TNFα and IL-4 levels in the supernatant after 24 h of T cell activation from HD (n = 4) or treatment naïve CLL patients (n = 4) in the presence of BTKi. D Representative CTV dilution histograms after 5 day proliferation assay in the presence of different BTKi treatments. E Effect on CD8 + and CD4 + T cell proliferation after 3, 5, and 7 days